Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Clinico-laboratory variants of the course and results of therapy of hepatitis-associated aplastic anemias in children].
Novichkova GA, Maschan MA, Kravchenko EG, Baĭdil'dina DD, Bogacheva NIu, Goronkova OV, Zharikova LI, Litvinov DV, Solopova GG, Suntsova EV, Shneĭder MM, Khachatrian LA, Skorobogatova EV, Shipitsyna IP, Trakhtman PE, Balashov DN, Maschan AA. Novichkova GA, et al. Among authors: zharikova li. Ter Arkh. 2007;79(7):57-61. Ter Arkh. 2007. PMID: 17802792 Russian.
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E, Roumiantseva J, Illarionova O, Lagoyko S, Miakova N, Zerkalenkova E, Zharikova L, Olshanskaya Y, Novichkova G, Maschan M, Henze G, Karachunskiy A, Popov A. Mikhailova E, et al. Br J Haematol. 2022 Jan;196(1):e6-e9. doi: 10.1111/bjh.17760. Epub 2021 Aug 3. Br J Haematol. 2022. PMID: 34346071 No abstract available.
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
Mikhailova E, Popov A, Roumiantseva J, Budanov O, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khachatryan L, Pshonkin A, Ponomareva N, Boichenko E, Varfolomeeva S, Dinikina J, Novichkova G, Henze G, Karachunskiy A. Mikhailova E, et al. J Immunother Cancer. 2024 Jun 6;12(6):e008213. doi: 10.1136/jitc-2023-008213. J Immunother Cancer. 2024. PMID: 38844406 Free PMC article. Clinical Trial.
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Leukemia. 2022 May;36(5):1382-1385. doi: 10.1038/s41375-022-01542-z. Epub 2022 Mar 23. Leukemia. 2022. PMID: 35322171 No abstract available.
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. J Cancer Res Clin Oncol. 2023 Jul;149(8):4629-4637. doi: 10.1007/s00432-022-04378-3. Epub 2022 Sep 28. J Cancer Res Clin Oncol. 2023. PMID: 36169717
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Leuk Res. 2022 Dec;123:106982. doi: 10.1016/j.leukres.2022.106982. Epub 2022 Oct 22. Leuk Res. 2022. PMID: 36332292 No abstract available.
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A, Henze G, Tsaur G, Budanov O, Roumiantseva J, Belevtsev M, Verzhbitskaya T, Movchan L, Lagoyko S, Zharikova L, Olshanskaya Y, Riger T, Valochnik A, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Aleinikova O, Fechina L, Karachunskiy A. Popov A, et al. Cancer Med. 2024 Apr;13(8):e7172. doi: 10.1002/cam4.7172. Cancer Med. 2024. PMID: 38651186 Free PMC article.
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, Boyakova E, Movchan L, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Pediatr Blood Cancer. 2023 Jun;70(6):e30295. doi: 10.1002/pbc.30295. Epub 2023 Mar 28. Pediatr Blood Cancer. 2023. PMID: 36975157
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL.
Popov A, Henze G, Roumiantseva J, Bydanov O, Belevtsev M, Verzhbitskaya T, Movchan L, Tsaur G, Lagoyko S, Zharikova L, Myakova N, Litvinov D, Khlebnikova O, Streneva O, Stolyarova E, Ponomareva N, Novichkova G, Fechina L, Aleinikova O, Karachunskiy A. Popov A, et al. Cancers (Basel). 2023 Nov 23;15(23):5547. doi: 10.3390/cancers15235547. Cancers (Basel). 2023. PMID: 38067249 Free PMC article.
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
Popov A, Henze G, Roumiantseva J, Budanov O, Verzhbitskaya T, Boyakova E, Tsaur G, Fadeeva M, Lagoyko S, Zharikova L, Miakova N, Litvinov D, Khlebnikova O, Streneva O, Ponomareva N, Novichkova G, Fechina L, Karachunskiy A. Popov A, et al. Leuk Res. 2023 Feb;125:106998. doi: 10.1016/j.leukres.2022.106998. Epub 2022 Dec 16. Leuk Res. 2023. PMID: 36566537 No abstract available.